Assembly Biosciences’ (ASMB) Neutral Rating Reiterated at HC Wainwright

Assembly Biosciences (NASDAQ:ASMB)‘s stock had its “neutral” rating restated by equities research analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports.

Assembly Biosciences Stock Performance

Shares of Assembly Biosciences stock opened at $11.01 on Monday. Assembly Biosciences has a 52-week low of $10.27 and a 52-week high of $19.93. The stock has a market capitalization of $69.98 million, a price-to-earnings ratio of -1.64 and a beta of 0.62. The company has a fifty day moving average of $12.91 and a 200-day moving average of $15.13.

Assembly Biosciences (NASDAQ:ASMB) last announced its quarterly earnings data on Thursday, March 20th. The biopharmaceutical company reported ($1.57) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.75) by $0.18. Assembly Biosciences had a negative net margin of 144.05% and a negative return on equity of 121.46%. The company had revenue of $7.36 million during the quarter, compared to analysts’ expectations of $7.05 million. On average, equities research analysts forecast that Assembly Biosciences will post -6.87 earnings per share for the current fiscal year.

Insider Buying and Selling at Assembly Biosciences

In other news, Director Michael Houghton purchased 3,202 shares of the company’s stock in a transaction on Monday, December 30th. The stock was acquired at an average price of $15.61 per share, with a total value of $49,983.22. Following the transaction, the director now directly owns 3,202 shares of the company’s stock, valued at approximately $49,983.22. This represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 5.10% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Assembly Biosciences

Several institutional investors have recently added to or reduced their stakes in ASMB. Gilead Sciences Inc. purchased a new stake in Assembly Biosciences during the 4th quarter valued at $34,865,000. Peapod Lane Capital LLC purchased a new stake in Assembly Biosciences during the 4th quarter valued at $994,000. B Group Inc. purchased a new stake in Assembly Biosciences during the 4th quarter valued at $799,000. Monimus Capital Management LP purchased a new stake in shares of Assembly Biosciences in the 4th quarter worth about $664,000. Finally, Renaissance Technologies LLC lifted its position in shares of Assembly Biosciences by 44.3% in the 4th quarter. Renaissance Technologies LLC now owns 94,711 shares of the biopharmaceutical company’s stock worth $1,495,000 after purchasing an additional 29,087 shares during the period. Hedge funds and other institutional investors own 19.92% of the company’s stock.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.